On Jun 29, 2018 Outperform Rating Received InflaRx (IFRX) at Raymond James with $44 Target.

June 29, 2018 - By Joshua Cleveland

What Price Target Has Raymond James Given InflaRx (IFRX)

Stock research analysts at Raymond James gave Outperform rating and has target of $44 on IFRX’s shares. On Thursday morning a coverage has started with InflaRx (IFRX)‘s stock.

InflaRx N.V. (NASDAQ:IFRX) Ratings Coverage

In total 5 analysts cover InflaRx (IFRX). “Buy” rating has 5, “Sell” are 0, while 0 are “Hold”. (IFRX) has 100% bullish analysts. 9 are the (IFRX)’s ratings reports on Jun 29, 2018 according to StockzIntelligence Inc. On Thursday, March 29 FBR Capital maintained InflaRx N.V. (NASDAQ:IFRX) with “Buy” rating. On Friday, May 18 the stock of InflaRx N.V. (NASDAQ:IFRX) earned “Buy” rating by Leerink Swann. On Thursday, March 8 the firm earned “Buy” rating by FBR Capital. On Wednesday, February 7 the firm earned “Buy” rating by FBR Capital. On Thursday, May 17 the rating was maintained by FBR Capital with “Buy”. On Monday, April 2 the stock has “Buy” rating by Leerink Swann.

IFRX touched $30.66 during the last trading session after $0.85 change.Currently InflaRx N.V. is after 0.00% change in last June 29, 2017. IFRX has 27,210 shares volume. IFRX underperformed the S&P500 by 12.57%.

InflaRx N.V. (NASDAQ:IFRX)’s earnings release is anticipated by WallStreet on August, 16, as reported by Faxor. Wall Street sees -18.37 % EPS growth as of August, 16.

InflaRx N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing inhibitors using C5a technology primarily in the United States and Europe.The firm is valued at $786.80 million. The Company’s C5a is an inflammatory mediator involved in the enhancement of a variety of autoimmune and other inflammatory diseases.Currently it has negative earnings. The company's lead product candidate is IFX-1, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that is in the Phase IIb clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; to treat ANCA-associated vasculitis, a rare and life-threatening autoimmune disease; and for the treatment of other chronic/autoimmune diseases.

Another two news for InflaRx N.V. (NASDAQ:IFRX) were briefly brought out by: Nasdaq.com on June 28, 2018 with title “InflaRx Receives IND Approval from the FDA to Start its Phase II Clinical Trial of IFX-1 in ANCA-Associated Vasculitis”. The other Globenewswire.com‘s article was titled “InflaRx Opens New Research Facility in Ann Arbor” and brought out on June 05, 2018.

InflaRx N.V. (NASDAQ:IFRX) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.